Source: International Congress 2019 – ECMO, ECCO2R and other rescue therapies in acute respiratory failure
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Hauschild (Hannover, Germany), I. Temitayo (Hannover, Germany), C. Schrimpf (Hannover, Germany), T. Welte (Hannover, Germany), H. Haller (Hannover, Germany), S. David (Hannover, Germany). Dual inhibition of Angiopoietin-2 and VEGF-A with a monoclonal antibody improves pulmonary capillary leakage in murine experimental sepsis. 2174

Member's Comments

No comment yet.

Related content which might interest you: Endothelial eNAMPT amplifies pre-clinical acute lung injury: efficacy of an eNAMPT-neutralising monoclonal antibody Source: Eur Respir J, 57 (5) 2002536; 10.1183/13993003.02536-2020 Year: 2021 Rapid reversal of radiation-induced murine pneumonitis by treatment with the anti-CTGF monoclonal antibody FG-3019 Source: Annual Congress 2011 - Experimental models and research in diffuse parenchymal lung diseases Year: 2011 Neutralization of CXCL12 reverses established pulmonary hypertension in the sugen-hypoxia rat model Source: International Congress 2017 – Experimental PH Year: 2017 VEGF gene transfer enhances fibrosis but improves pulmonary hemodynamics in experimental pulmonary fibrosis Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008 Endotoxin reduces VEGF receptor-2 in mouse lung and heart Source: Eur Respir J 2003; 22: Suppl. 45, 585s Year: 2003 Hypoxia-induced increase in NO production and eNOS expression by murine pulmonary microvascular endothelial cells Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling Year: 2006 Vascular endothelial growth factor (VEGF) mRNA isoforms in an animal model of acute lung injury Source: Annual Congress 2003 - Animal models of lung injury: useful or not? Year: 2003 Anti-CTGF antibody attenuates silica-induced lung fibrosis in rats Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018 Implication of aquaporin-1 in the stress response of human pulmonary microvascular endothelial cells Source: International Congress 2019 – Biomarkers, laboratory findings and pre-clinical data in acute respiratory failure Year: 2019 VEGF reduces pulmonary hypertension and vascular remodeling in pulmonary fibrosis through reduced endothelial apoptosis Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009 Vascular endothelial growth factor (VEGF) and CD31 expression in experimental prosthetic tracheal replacement Source: Annual Congress 2009 - Current challenges in thoracic surgery Year: 2009 Intravenous anti-vascular endothelial growth factor antibody decreases pleural fluid volume in experimental pleurodesis induced by silver nitrate Source: Annual Congress 2007 - Pleural diseases Year: 2007 Identification of target antigens of anti-fibroblast antibodies in pulmonary arterial hypertension Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension Year: 2008 Production of a novel isoform of vascular endothelial growth factor (VEGF) by the normal human lung Source: Eur Respir J 2006; 28: Suppl. 50, 822s Year: 2006 FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis Source: Eur Respir J 2016; 47:1481-1491 Year: 2016 Iloprost protects against lung endothelial barrier dysfunction and vascular leak via Rap1 Source: Annual Congress 2009 - Crossing the line: alveolo-capillary barrier control in acute lung injury Year: 2009 Increased binding activity of hypoxia inducible factor (HIF)-1α to vascular endothelial growth factor (VEGF) promoter region mediates enhanced vascular permeability in the lung of cystic fibrosis (CF) patients Source: Eur Respir J 2003; 22: Suppl. 45, 173s Year: 2003 Regulation of connexins by hypoxia in rat pulmonary vascular cells in an in vitro model of pulmonary hypertension Source: International Congress 2017 – Experimental PH Year: 2017 Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011